Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

To join this study, you would need to have cancer that has spread or is advanced, and doctors must be able to measure or see your cancer. Generally, you should be able to carry out your daily activities with little to no difficulty. Your blood counts (like red blood cells, white blood cells, and platelets) need to be at a healthy level without needing recent blood transfusions or special injections to boost them. Your kidney function also needs to be working well enough.

For most people taking part, your liver function would need to be within a normal range. However, this study specifically includes a group of people with moderate liver problems. If you have moderate liver problems, your liver test results would show certain changes, but you must still be able to understand and agree to take part in the study, even if you have a condition called 'hepatic encephalopathy' which can sometimes affect thinking.

There are also some reasons why you wouldn't be able to join. For example, if you have very poor veins, have recently donated a lot of blood, or have had other cancer treatments (like chemotherapy or radiation) very recently. Also, if you have another active cancer or if your cancer has spread to your brain in certain ways, you might not be able to participate. Your study doctor will go through all these details with you carefully.

If you decide to take part in this study, you will receive the study drug, sacituzumab govitecan, as an injection. The study team will carefully monitor your health throughout. This will involve regular visits to the clinic for check-ups, which might include blood tests, physical examinations, and scans to see how you are responding to the treatment and to check for any side effects. The exact number of visits and tests will be explained to you by the study team. You will be closely followed to ensure your safety and that the treatment is working as intended. The total length of your participation will depend on how you respond to the treatment and the study plan, but ongoing monitoring will be a key part of your involvement.